company background image
CAPR logo

Capricor Therapeutics NasdaqCM:CAPR Stock Report

Last Price

US$5.99

Market Cap

US$188.7m

7D

-3.4%

1Y

32.8%

Updated

26 May, 2024

Data

Company Financials +

Capricor Therapeutics, Inc.

NasdaqCM:CAPR Stock Report

Market Cap: US$188.7m

CAPR Stock Overview

A clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.

CAPR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Capricor Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Capricor Therapeutics
Historical stock prices
Current Share PriceUS$5.99
52 Week HighUS$8.22
52 Week LowUS$2.68
Beta4.07
1 Month Change10.72%
3 Month Change51.26%
1 Year Change32.82%
3 Year Change58.05%
5 Year Change91.50%
Change since IPO-85.74%

Recent News & Updates

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Recent updates

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

Feb 01
Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Oct 14
We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result

Sep 25

Capricor Therapeutics slumps 9% on $75M stock offering

Jun 21

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

May 16
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Mar 13
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Capricor signs intellectual property license for COVID-19 serology test platform

Feb 01

Capricor and Lonza tie up in DMD development

Jan 12

Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19

Nov 24

Shareholder Returns

CAPRUS BiotechsUS Market
7D-3.4%-1.7%-0.3%
1Y32.8%7.1%25.4%

Return vs Industry: CAPR exceeded the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: CAPR exceeded the US Market which returned 25.4% over the past year.

Price Volatility

Is CAPR's price volatile compared to industry and market?
CAPR volatility
CAPR Average Weekly Movement9.9%
Biotechs Industry Average Movement11.3%
Market Average Movement5.9%
10% most volatile stocks in US Market16.0%
10% least volatile stocks in US Market2.8%

Stable Share Price: CAPR's share price has been volatile over the past 3 months.

Volatility Over Time: CAPR's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005102Linda Marbánwww.capricor.com

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.

Capricor Therapeutics, Inc. Fundamentals Summary

How do Capricor Therapeutics's earnings and revenue compare to its market cap?
CAPR fundamental statistics
Market capUS$188.70m
Earnings (TTM)-US$24.31m
Revenue (TTM)US$27.10m

7.0x

P/S Ratio

-7.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CAPR income statement (TTM)
RevenueUS$27.10m
Cost of RevenueUS$36.45m
Gross Profit-US$9.35m
Other ExpensesUS$14.96m
Earnings-US$24.31m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.77
Gross Margin-34.50%
Net Profit Margin-89.72%
Debt/Equity Ratio0%

How did CAPR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.